https://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rssBioCentury feeden-USCopyright 2026 BioCentury, Inc.RSS Generatorhttps://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/z8oGLhcsSyi6zlYTKFwihttps://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rsshttps://www.biocentury.com/article/659644/may-s-approvals-bring-fda-to-20-nmes-on-the-yearhttps://www.biocentury.com/article/659644/may-s-approvals-bring-fda-to-20-nmes-on-the-year?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEMAY’S APPROVALS BRING FDA TO 20 NMES ON THE YEARA look at last month’s approvals in the U.S.Fri, 05 Jun 2026 18:10:40 -0700https://www.biocentury.com/article/659660/ona-s-86-6m-venture-round-among-spain-s-biggest-for-a-biotech-finance-reporthttps://www.biocentury.com/article/659660/ona-s-86-6m-venture-round-among-spain-s-biggest-for-a-biotech-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEONA’S $86.6M VENTURE ROUND AMONG SPAIN’S BIGGEST FOR A BIOTECH: FINANCE REPORTPlus: Massive round for NewLimit; follow-ons for Jade and Mineralys; LongBio’s Hong Kong listing; and moreFri, 05 Jun 2026 17:53:34 -0700https://www.biocentury.com/article/659671/adcs-headline-first-in-human-development-at-ascohttps://www.biocentury.com/article/659671/adcs-headline-first-in-human-development-at-asco?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTADCS HEADLINE FIRST-IN-HUMAN DEVELOPMENT AT ASCO BioCentury’s analysis of 137 FIH studies highlighted at this year’s conferenceFri, 05 Jun 2026 17:48:56 -0700https://www.biocentury.com/article/659676/forbion-welcomes-mcdonald-from-novo-promotes-two-partnershttps://www.biocentury.com/article/659676/forbion-welcomes-mcdonald-from-novo-promotes-two-partners?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSFORBION WELCOMES MCDONALD FROM NOVO, PROMOTES TWO PARTNERSPlus: Management changes at Airna, Myriad Genetics and OncolyticsFri, 05 Jun 2026 17:29:32 -0700https://www.biocentury.com/article/659662/fred-hutch-s-sylvain-simon-named-rising-star-at-grand-rounds-u-s-in-seattlehttps://www.biocentury.com/article/659662/fred-hutch-s-sylvain-simon-named-rising-star-at-grand-rounds-u-s-in-seattle?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONFRED HUTCH’S SYLVAIN SIMON NAMED ‘RISING STAR’ AT GRAND ROUNDS U.S. IN SEATTLEChimeric T cell receptor platform could help prevent cancer relapse seen with CAR T cell therapiesThu, 04 Jun 2026 16:51:32 -0700https://www.biocentury.com/article/659669/meeting-sign-of-acting-fda-leadership-trying-to-right-the-shiphttps://www.biocentury.com/article/659669/meeting-sign-of-acting-fda-leadership-trying-to-right-the-ship?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWMEETING SIGN OF ACTING FDA LEADERSHIP TRYING TO RIGHT THE SHIPIn gathering with rare disease advocates, agency leadership stresses return to normal operations, respect for career staff, transparencyThu, 04 Jun 2026 16:32:22 -0700https://www.biocentury.com/article/659657/congressional-concern-growing-over-integration-of-chinese-u-s-biopharmahttps://www.biocentury.com/article/659657/congressional-concern-growing-over-integration-of-chinese-u-s-biopharma?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWCONGRESSIONAL CONCERN GROWING OVER INTEGRATION OF CHINESE, U.S. BIOPHARMA Legislation to limit in-licensing, add biotech to outbound investment controls pressures Trump administration to curtail biopharma engagement with ChinaThu, 04 Jun 2026 16:16:35 -0700https://www.biocentury.com/article/659622/servier-continues-m-a-buildout-acquires-edgewise-s-neuro-programshttps://www.biocentury.com/article/659622/servier-continues-m-a-buildout-acquires-edgewise-s-neuro-programs?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSSERVIER CONTINUES M&A BUILDOUT, ACQUIRES EDGEWISE’S NEURO PROGRAMS$1.6B buyout for sevasemten marks first big neuro move for ServierThu, 04 Jun 2026 13:19:46 -0700https://www.biocentury.com/article/659653/legend-s-ex-vivo-design-expertise-underpins-in-vivo-car-t-efficacyhttps://www.biocentury.com/article/659653/legend-s-ex-vivo-design-expertise-underpins-in-vivo-car-t-efficacy?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTLEGEND’S EX VIVO DESIGN EXPERTISE UNDERPINS IN VIVO CAR T EFFICACYLegend CEO Ying Huang discusses first-in-human in vivo CAR T results with BioCenturyWed, 03 Jun 2026 17:52:06 -0700https://www.biocentury.com/article/659652/science-spotlight-microglial-states-as-druggable-nodes-in-cns-diseasehttps://www.biocentury.com/article/659652/science-spotlight-microglial-states-as-druggable-nodes-in-cns-disease?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: MICROGLIAL STATES AS DRUGGABLE NODES IN CNS DISEASEBioCentury’s translational roundup also includes an atlas of tertiary lymphoid structuresWed, 03 Jun 2026 17:31:24 -0700https://www.biocentury.com/article/659595/fda-s-real-time-clinical-trials-initiative-may-have-real-but-unexpected-benefitshttps://www.biocentury.com/article/659595/fda-s-real-time-clinical-trials-initiative-may-have-real-but-unexpected-benefits?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWFDA’S REAL-TIME CLINICAL TRIALS INITIATIVE MAY HAVE REAL, BUT UNEXPECTED, BENEFITSAutomating data collection, prespecifying actionable signals could make trials faster and cheaper, and improve regulatory decisions Wed, 03 Jun 2026 17:19:21 -0700https://www.biocentury.com/article/659647/cancer-cases-cloud-efficacy-in-abivax-colitis-study-clinical-reporthttps://www.biocentury.com/article/659647/cancer-cases-cloud-efficacy-in-abivax-colitis-study-clinical-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTCANCER CASES CLOUD EFFICACY IN ABIVAX COLITIS STUDY: CLINICAL REPORTAbivax slides on positive efficacy data, reports of cancer cases in participants; plus other readoutsTue, 02 Jun 2026 17:46:56 -0700https://www.biocentury.com/article/659614/allen-institute-launches-atlas-to-therapy-push-in-neurodegenerationhttps://www.biocentury.com/article/659614/allen-institute-launches-atlas-to-therapy-push-in-neurodegeneration?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONALLEN INSTITUTE LAUNCHES ATLAS-TO-THERAPY PUSH IN NEURODEGENERATIONBrain Health Accelerator aims to turn cellular maps and disease data into precision gene therapies for neurodegenerationTue, 02 Jun 2026 17:01:43 -0700https://www.biocentury.com/article/659645/fda-reviving-drugs-derailed-under-makary-and-prasadhttps://www.biocentury.com/article/659645/fda-reviving-drugs-derailed-under-makary-and-prasad?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONFDA REVIVING DRUGS DERAILED UNDER MAKARY AND PRASADNew leadership at agency is reversing or reconsidering controversial regulatory setbacks Tue, 02 Jun 2026 16:15:38 -0700https://www.biocentury.com/article/659635/akeso-s-ivonescimab-meets-next-phase-iii-lung-cancer-goal-as-competitors-line-uphttps://www.biocentury.com/article/659635/akeso-s-ivonescimab-meets-next-phase-iii-lung-cancer-goal-as-competitors-line-up?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTAKESO’S IVONESCIMAB MEETS NEXT PHASE III LUNG CANCER GOAL, AS COMPETITORS LINE UPIvonescimab leads to overall survival benefit at interim readout of HARMONi-6 presented at ASCO Mon, 01 Jun 2026 18:23:51 -0700https://www.biocentury.com/article/659637/kelonia-data-advance-the-durability-narrative-around-in-vivo-car-ts-at-ascohttps://www.biocentury.com/article/659637/kelonia-data-advance-the-durability-narrative-around-in-vivo-car-ts-at-asco?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTKELONIA DATA ADVANCE THE DURABILITY NARRATIVE AROUND IN VIVO CAR TS AT ASCOPlus: ADC results from Salubris and BeOne, immunocytokine data from Innovent and moreMon, 01 Jun 2026 18:21:41 -0700https://www.biocentury.com/article/659626/the-revolution-will-be-ras-on-in-pancreatic-cancerhttps://www.biocentury.com/article/659626/the-revolution-will-be-ras-on-in-pancreatic-cancer?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTTHE REVOLUTION WILL BE RAS(ON) IN PANCREATIC CANCERIn doubling survival in PDAC without major safety signals, RevMed therapy delivers ASCO readout that settles debate over selective RAS(ON) inhibition Mon, 01 Jun 2026 17:23:30 -0700https://www.biocentury.com/article/659628/avenzo-turns-to-rallybio-for-path-to-nasdaq-deals-reporthttps://www.biocentury.com/article/659628/avenzo-turns-to-rallybio-for-path-to-nasdaq-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSAVENZO TURNS TO RALLYBIO FOR PATH TO NASDAQ: DEALS REPORTPlus: Lilly’s pair of Asian deals with Hanmi and Haisco; Edgewise/Servier; and moreMon, 01 Jun 2026 16:45:45 -0700https://www.biocentury.com/article/659629/asco-advances-china-innovation-u-s-science-under-threat-a-biocentury-podcasthttps://www.biocentury.com/article/659629/asco-advances-china-innovation-u-s-science-under-threat-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTASCO ADVANCES, CHINA INNOVATION & U.S. SCIENCE UNDER THREAT — A BIOCENTURY PODCAST Data from RevMed, Akeso in the spotlight in Chicago. Plus: BioCentury’s take on China competition, OMB’s grant proposalMon, 01 Jun 2026 15:56:52 -0700https://www.biocentury.com/article/659617/cmo-roberts-to-succeed-chang-as-allogene-ceohttps://www.biocentury.com/article/659617/cmo-roberts-to-succeed-chang-as-allogene-ceo?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSCMO ROBERTS TO SUCCEED CHANG AS ALLOGENE CEO Plus: FDA veteran Fashoyin-Aje lands at AZ and other biopharma management movesFri, 29 May 2026 17:22:38 -0700https://www.biocentury.com/article/659615/pharma-ceo-silence-is-complicity-in-the-destruction-of-u-s-sciencehttps://www.biocentury.com/article/659615/pharma-ceo-silence-is-complicity-in-the-destruction-of-u-s-science?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYPHARMA CEO SILENCE IS COMPLICITY IN THE DESTRUCTION OF U.S. SCIENCEWhy leaders of the U.S.’s biggest drug companies should use their influence to stop a ruinous proposalFri, 29 May 2026 17:01:44 -0700https://www.biocentury.com/article/659608/busy-june-at-fda-with-11-upcoming-pdufa-dateshttps://www.biocentury.com/article/659608/busy-june-at-fda-with-11-upcoming-pdufa-dates?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEBUSY JUNE AT FDA WITH 11 UPCOMING PDUFA DATESAt least eight new products and three new indications await decisionsFri, 29 May 2026 16:58:32 -0700https://www.biocentury.com/article/659586/cardiovascular-in-licensing-play-kardigan-looking-for-quick-path-to-ipo-finance-reporthttps://www.biocentury.com/article/659586/cardiovascular-in-licensing-play-kardigan-looking-for-quick-path-to-ipo-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCECARDIOVASCULAR IN-LICENSING PLAY KARDIGAN LOOKING FOR QUICK PATH TO IPO: FINANCE REPORTPlus: Editas’ follow-on, Clearnote’s series D and moreFri, 29 May 2026 12:59:34 -0700https://www.biocentury.com/article/659610/covering-12-oncology-programs-pfizer-deal-is-innovent-s-latest-step-toward-global-goalshttps://www.biocentury.com/article/659610/covering-12-oncology-programs-pfizer-deal-is-innovent-s-latest-step-toward-global-goals?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSCOVERING 12 ONCOLOGY PROGRAMS, PFIZER DEAL IS INNOVENT’S LATEST STEP TOWARD GLOBAL GOALSChina-based innovator receives $650M up front, aims to co-commercialize more programs globally in wake of 2025 Takeda dealFri, 29 May 2026 12:51:56 -0700https://www.biocentury.com/article/659598/playing-defense-is-a-losing-strategy-the-u-s-needs-an-offensive-biopharma-planhttps://www.biocentury.com/article/659598/playing-defense-is-a-losing-strategy-the-u-s-needs-an-offensive-biopharma-plan?utm_source=bc_rss&utm_medium=rssBIOCENTURY | GUEST COMMENTARYPLAYING DEFENSE IS A LOSING STRATEGY: THE U.S. NEEDS AN OFFENSIVE BIOPHARMA PLANThe U.S. still leads in biopharma innovation. Defensive policy alone will lose it Thu, 28 May 2026 17:58:00 -0700https://www.biocentury.com/article/659601/three-decades-in-biotech-richard-pops-on-policy-drug-pricing-and-leadershiphttps://www.biocentury.com/article/659601/three-decades-in-biotech-richard-pops-on-policy-drug-pricing-and-leadership?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWTHREE DECADES IN BIOTECH: RICHARD POPS ON POLICY, DRUG PRICING AND LEADERSHIPAlkermes CEO on how policy, economics shape drug development, from the IRA to MFN and beyondThu, 28 May 2026 14:28:02 -0700https://www.biocentury.com/article/659600/take-your-head-out-of-the-sand-on-china-a-perspectivehttps://www.biocentury.com/article/659600/take-your-head-out-of-the-sand-on-china-a-perspective?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYTAKE YOUR HEAD OUT OF THE SAND ON CHINA: A PERSPECTIVEIf half the time spent on hysteria about China went to competing on merits, biotechs and patients would be much better servedThu, 28 May 2026 12:16:20 -0700https://www.biocentury.com/article/659592/post-ipo-kailera-looks-beyond-obesity-to-mashhttps://www.biocentury.com/article/659592/post-ipo-kailera-looks-beyond-obesity-to-mash?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTPOST-IPO, KAILERA LOOKS BEYOND OBESITY TO MASHKAI-4729 adds Kailera and Hengrui to a growing MASH pipeline testing whether glucagon agonism can enhance incretin therapy’s liver benefitWed, 27 May 2026 15:43:24 -0700https://www.biocentury.com/article/659590/science-spotlight-silencing-seizures-by-fixing-gene-mutationshttps://www.biocentury.com/article/659590/science-spotlight-silencing-seizures-by-fixing-gene-mutations?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: SILENCING SEIZURES BY FIXING GENE MUTATIONSBioCentury’s translational roundup also includes a method to restore tertiary lymphoid structures in lung cancer, and papers from six newcosWed, 27 May 2026 15:40:10 -0700https://www.biocentury.com/article/659588/blackstone-backs-apogee-s-atopic-dermatitis-therapy-as-it-heads-to-phase-iiihttps://www.biocentury.com/article/659588/blackstone-backs-apogee-s-atopic-dermatitis-therapy-as-it-heads-to-phase-iii?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSBLACKSTONE BACKS APOGEE’S ATOPIC DERMATITIS THERAPY AS IT HEADS TO PHASE IIIDeal for up to $1.3B accompanies new data showing efficacy signal for long-acting anti-IL-13 moleculeWed, 27 May 2026 15:11:25 -0700https://www.biocentury.com/article/659580/merck-s-post-keytruda-nsclc-play-advances-as-rivals-close-in-at-ascohttps://www.biocentury.com/article/659580/merck-s-post-keytruda-nsclc-play-advances-as-rivals-close-in-at-asco?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMERCK'S POST-KEYTRUDA NSCLC PLAY ADVANCES AS RIVALS CLOSE IN AT ASCOTROP2 ADC and PD-L1 x VEGF bispecific show efficacy in first-line combo studiesTue, 26 May 2026 17:45:38 -0700https://www.biocentury.com/article/659581/asco-preview-china-policy-adc-linkers-a-biocentury-podcasthttps://www.biocentury.com/article/659581/asco-preview-china-policy-adc-linkers-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTASCO PREVIEW, CHINA POLICY, ADC LINKERS — A BIOCENTURY PODCASTPlus: Proposal by Rep. Auchincloss to modernize U.S. clinical trialsTue, 26 May 2026 17:08:46 -0700https://www.biocentury.com/article/659570/ema-s-chmp-backs-four-new-medicines-at-may-meetinghttps://www.biocentury.com/article/659570/ema-s-chmp-backs-four-new-medicines-at-may-meeting?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEEMA'S CHMP BACKS FOUR NEW MEDICINES AT MAY MEETINGOral Wegovy for obesity headlines 11 recommended label extensionsTue, 26 May 2026 17:02:50 -0700https://www.biocentury.com/article/659578/lilly-steps-up-in-vaccines-with-three-acquisitions-deals-reporthttps://www.biocentury.com/article/659578/lilly-steps-up-in-vaccines-with-three-acquisitions-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSLILLY STEPS UP IN VACCINES WITH THREE ACQUISITIONS: DEALS REPORTPharma to obtain Shingrix competitor, clinical S. aureus product, nanoparticle technology and more via trio of takeoutsTue, 26 May 2026 16:26:34 -0700https://www.biocentury.com/article/659573/asco-to-spotlight-pancreatic-cancer-innovation-beyond-krashttps://www.biocentury.com/article/659573/asco-to-spotlight-pancreatic-cancer-innovation-beyond-kras?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTASCO TO SPOTLIGHT PANCREATIC CANCER INNOVATION BEYOND KRASRevolution’s daraxonrasib data will be the marquee event, but abstracts highlight ADCs, bispecifics and diagnostics broadening the field’s approachFri, 22 May 2026 17:15:52 -0700https://www.biocentury.com/article/659571/trump-administration-considering-restrictions-on-china-dealshttps://www.biocentury.com/article/659571/trump-administration-considering-restrictions-on-china-deals?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWTRUMP ADMINISTRATION CONSIDERING RESTRICTIONS ON CHINA DEALSChina hawks are calling for outbound investment bans to be extended to biotechFri, 22 May 2026 16:43:02 -0700https://www.biocentury.com/article/659566/parabilis-follows-up-regeneron-deal-with-ipo-filing-public-equity-reporthttps://www.biocentury.com/article/659566/parabilis-follows-up-regeneron-deal-with-ipo-filing-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEPARABILIS FOLLOWS UP REGENERON DEAL WITH IPO FILING: PUBLIC EQUITY REPORTPlus: Mentari’s reverse merger, offerings by Relay and Immix, and moreFri, 22 May 2026 13:35:56 -0700https://www.biocentury.com/article/659562/europe-s-next-big-growth-fund-could-help-narrow-biotech-s-capital-gaphttps://www.biocentury.com/article/659562/europe-s-next-big-growth-fund-could-help-narrow-biotech-s-capital-gap?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEEUROPE’S NEXT BIG GROWTH FUND COULD HELP NARROW BIOTECH’S CAPITAL GAPEQT’s €5B cross-sector fund could give European biotechs another homegrown option for growth capitalFri, 22 May 2026 12:52:16 -0700https://www.biocentury.com/article/659558/fewer-but-more-concentrated-early-stage-bets-so-far-in-1h26https://www.biocentury.com/article/659558/fewer-but-more-concentrated-early-stage-bets-so-far-in-1h26?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEFEWER BUT MORE CONCENTRATED EARLY-STAGE BETS SO FAR IN 1H26With about a month remaining, seed/series A activity in 1H26 appears down from past halves, but median round size may reach a 10-year highThu, 21 May 2026 14:28:22 -0700https://www.biocentury.com/article/659553/backed-by-westlake-oorja-planning-mid-stage-study-of-ipf-candidate-venture-reporthttps://www.biocentury.com/article/659553/backed-by-westlake-oorja-planning-mid-stage-study-of-ipf-candidate-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEBACKED BY WESTLAKE, OORJA PLANNING MID-STAGE STUDY OF IPF CANDIDATE: VENTURE REPORTPlus: Rounds for cross-border companies Accro and Full-Life, and moreThu, 21 May 2026 12:17:25 -0700https://www.biocentury.com/article/659549/retatrutide-data-strengthen-lilly-s-hand-in-high-bmi-obesityhttps://www.biocentury.com/article/659549/retatrutide-data-strengthen-lilly-s-hand-in-high-bmi-obesity?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTRETATRUTIDE DATA STRENGTHEN LILLY’S HAND IN HIGH-BMI OBESITYPhase III data put weight loss above CagriSema’s benchmark, with tolerability that may be good enough to preserve a commercial edgeThu, 21 May 2026 12:09:28 -0700https://www.biocentury.com/article/659538/hengrui-s-deal-economics-pharma-biotech-and-newco-breakdownhttps://www.biocentury.com/article/659538/hengrui-s-deal-economics-pharma-biotech-and-newco-breakdown?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEHENGRUI’S DEAL ECONOMICS: PHARMA, BIOTECH AND NEWCO BREAKDOWNHow Hengrui’s out-licensing deals stack up across partner types, and why last week’s BMS partnership was an outlierWed, 20 May 2026 16:59:02 -0700https://www.biocentury.com/article/659546/auchincloss-developing-clinical-trials-package-to-enhance-u-s-competitivenesshttps://www.biocentury.com/article/659546/auchincloss-developing-clinical-trials-package-to-enhance-u-s-competitiveness?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWAUCHINCLOSS DEVELOPING CLINICAL TRIALS PACKAGE TO ENHANCE U.S. COMPETITIVENESSMassachusetts Democrat seeking feedback on draft proposalWed, 20 May 2026 15:32:43 -0700https://www.biocentury.com/article/659335/poplar-expanding-food-allergy-treatment-with-deeper-ige-depletionhttps://www.biocentury.com/article/659335/poplar-expanding-food-allergy-treatment-with-deeper-ige-depletion?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEPOPLAR: EXPANDING FOOD ALLERGY TREATMENT WITH DEEPER IGE DEPLETIONBy dismantling both IgE signaling and production, start-up aims to create options for patients not reached by XolairWed, 20 May 2026 12:27:47 -0700https://www.biocentury.com/article/659545/as-griffith-retires-dittrich-returns-to-amgen-takes-cfo-rolehttps://www.biocentury.com/article/659545/as-griffith-retires-dittrich-returns-to-amgen-takes-cfo-role?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSAS GRIFFITH RETIRES, DITTRICH RETURNS TO AMGEN, TAKES CFO ROLEPlus: Miralles moves into top R&D position at Artiva; and moreWed, 20 May 2026 12:06:44 -0700https://www.biocentury.com/article/659517/remembering-reiri-visionary-investor-who-championed-japan-s-biotech-sectorhttps://www.biocentury.com/article/659517/remembering-reiri-visionary-investor-who-championed-japan-s-biotech-sector?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSREMEMBERING REIRI: VISIONARY INVESTOR WHO CHAMPIONED JAPAN’S BIOTECH SECTOR Reiri Miura helped build venture firms, companies and networks that strengthened Japan’s biotech industryTue, 19 May 2026 17:31:44 -0700https://www.biocentury.com/article/659535/dueling-memos-are-a-case-study-in-the-politicization-of-scientific-datahttps://www.biocentury.com/article/659535/dueling-memos-are-a-case-study-in-the-politicization-of-scientific-data?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYDUELING MEMOS ARE A CASE STUDY IN THE POLITICIZATION OF SCIENTIFIC DATARelease of underlying data shows how Makary, Prasad, Høeg exaggerated facts to justify gutting vaccine regulationTue, 19 May 2026 16:17:10 -0700https://www.biocentury.com/article/659283/if-ai-becomes-table-stakes-where-is-the-differentiation-a-perspectivehttps://www.biocentury.com/article/659283/if-ai-becomes-table-stakes-where-is-the-differentiation-a-perspective?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYIF AI BECOMES TABLE STAKES, WHERE IS THE DIFFERENTIATION? A PERSPECTIVEShared drug design tools could raise biotech’s baseline capabilities, putting more weight on target selection, validation and iteration speedTue, 19 May 2026 12:56:31 -0700https://www.biocentury.com/article/659515/the-small-but-diverse-lgr5-pipelinehttps://www.biocentury.com/article/659515/the-small-but-diverse-lgr5-pipeline?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTETHE SMALL BUT DIVERSE LGR5 PIPELINEAt least four LGR5-targeted therapies are in development for cancerTue, 19 May 2026 12:43:20 -0700https://www.biocentury.com/article/659510/fda-obesity-targets-and-the-rise-of-dacs-a-biocentury-podcasthttps://www.biocentury.com/article/659510/fda-obesity-targets-and-the-rise-of-dacs-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWFDA, OBESITY TARGETS AND THE RISE OF DACS — A BIOCENTURY PODCASTWhat’s next for FDA as top officials oustedMon, 18 May 2026 16:59:06 -0700